2,4-thiazolidinedione has been researched along with Cardiovascular Diseases in 31 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nine of the eleven studies showed significant decrease in body weight among participants in the exenatide group compared with placebo or control group while the other two studies did not report statistically significant differences in body weight." | 4.93 | The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review. ( Ojo, O, 2016) |
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| " Safety was assessed by adverse events, hypoglycemia, and body weight." | 2.78 | Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials. ( Allen, E; Bryzinski, B; Cook, W; Frederich, R; Slater, J, 2013) |
| "Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements." | 2.42 | Insulin sensitizers. ( Basu, A; Kudva, YC; Zangeneh, F, 2003) |
| "Insulin resistance is a key metabolic defect in type 2 diabetes that is exacerbated by obesity, especially if the excess adiposity is located intra-abdominally/centrally." | 2.42 | Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. ( Smith, SA, 2003) |
| "The incidence of obesity and type 2 diabetes mellitus (DM2) in the United States has been increasing dramatically over the past 15 years, and is now at epidemic proportions." | 2.42 | Cardiovascular implications of thiazolidinedione therapy. ( King, D; Lamb, RE, 2004) |
| "Multicentre, randomized, clinical trials that included over 100 participants comparing antidiabetic agents with a placebo or a different antidiabetic agent and reporting major adverse cardiovascular events (MACEs), or primarily reporting heart failure, were searched in the PubMed, Embase and Cochrane databases." | 1.91 | Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials. ( Frias, JP; Lim, S; Sohn, M, 2023) |
| "We found no increased risk of acute pancreatitis comparing 49,374 DPP-4I initiators to 132,223 sulfonylurea initiators (weighted HR 1." | 1.48 | The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. ( Buse, JB; Hong, JL; Jonsson Funk, M; Pate, V; Stürmer, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (61.29) | 29.6817 |
| 2010's | 9 (29.03) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Abushamat, LA | 1 |
| Reusch, JEB | 1 |
| Sohn, M | 1 |
| Frias, JP | 1 |
| Lim, S | 1 |
| Elsisi, GH | 1 |
| Anwar, MM | 1 |
| Khattab, M | 1 |
| Elebrashy, I | 1 |
| Wafa, A | 1 |
| Elhadad, H | 1 |
| Awad, M | 1 |
| Carapinha, JL | 1 |
| Ha, KH | 1 |
| Kim, B | 1 |
| Choi, H | 1 |
| Kim, DJ | 1 |
| Kim, HC | 1 |
| Hong, JL | 1 |
| Buse, JB | 1 |
| Jonsson Funk, M | 1 |
| Pate, V | 1 |
| Stürmer, T | 1 |
| Cook, W | 1 |
| Bryzinski, B | 1 |
| Slater, J | 1 |
| Frederich, R | 1 |
| Allen, E | 1 |
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 1 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Ojo, O | 1 |
| Ribowsky, J | 1 |
| Covino, J | 1 |
| Simpson, F | 1 |
| Whitehead, JP | 1 |
| Krumholz, HM | 1 |
| Mori, S | 1 |
| Benetti, E | 1 |
| Patel, NS | 1 |
| Collino, M | 1 |
| Goldstein, BJ | 1 |
| Zimmet, P | 1 |
| Zangeneh, F | 1 |
| Kudva, YC | 1 |
| Basu, A | 1 |
| Drexler, AJ | 1 |
| Braunstein, S | 2 |
| Uwaifo, GI | 1 |
| Ratner, RE | 1 |
| Wyne, KL | 1 |
| Fonseca, V | 1 |
| Smith, SA | 1 |
| Kawamori, R | 1 |
| Kadowaki, T | 1 |
| Ishida, H | 1 |
| Lamb, RE | 1 |
| King, D | 1 |
| Iwamoto, Y | 1 |
| Ziegler, D | 1 |
| Ziegler, R | 1 |
| Hartge, MM | 1 |
| Kintscher, U | 1 |
| Unger, T | 1 |
| Legro, RS | 1 |
| Cohen-Solal, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Adding Dapagliflozin and Furosemide in Diabetic Patients (Type 2) With Decompensated Heart Failure With Reduced Ejection Fraction (HFrEF)[NCT04385589] | Phase 4 | 100 participants (Actual) | Interventional | 2020-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for 2,4-thiazolidinedione and Cardiovascular Diseases
| Article | Year |
|---|---|
Evolving Concepts of Type 2 Diabetes Management.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidy | 2021 |
The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
Topics: Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exenatide; Female; Glyc | 2016 |
Adiponectin--it's all about the modifications.
Topics: Adiponectin; Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; PPAR gamma; Protei | 2010 |
[Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases].
Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Diseases; Diabetes Complications; Diphosphonate | 2011 |
The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.
Topics: Animals; Cardiovascular Diseases; Disease Management; Humans; Ligands; Metabolic Syndrome; PPAR delt | 2011 |
Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Metabolic Syndrome; Thiazoles; Thiazolidinedio | 2002 |
Insulin sensitizers.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 2003 |
Lessons learned from landmark trials of type 2 diabetes mellitus and potential applications to clinical practice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans | 2003 |
Cardiovascular disease and benefits of thiazolidinediones.
Topics: Arteriosclerosis; Blood Pressure; Blood Vessels; Cardiovascular Diseases; Humans; Hypercholesterolem | 2003 |
New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2003 |
The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease.
Topics: Cardiovascular Diseases; Humans; Hyperinsulinism; Insulin Resistance; Receptors, Cytoplasmic and Nuc | 2003 |
Free fatty acids and type 2 diabetes mellitus.
Topics: Adipocytes; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; | 2003 |
Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
Topics: Adipose Tissue; Body Weight; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Diabetes Melli | 2003 |
Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones.
Topics: Adipocytes; Cardiovascular Diseases; Humans; Insulin Resistance; Liver; Muscle, Skeletal; Risk; Thia | 2003 |
Cardiovascular implications of thiazolidinedione therapy.
Topics: Cardiovascular Diseases; Contraindications; Decision Trees; Diabetes Mellitus, Type 2; Edema; Heart | 2004 |
[Selection of oral antidiabetic drugs].
Topics: Acarbose; Administration, Oral; Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Enzy | 2005 |
Type 2 diabetes as an inflammatory cardiovascular disorder.
Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Arteriosclerosis; Cardiovascular Diseases; Diabetes | 2005 |
Endothelial dysfunction and its role in diabetic vascular disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
[Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion].
Topics: Cardiology; Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Echocardiography; | 2002 |
1 trial available for 2,4-thiazolidinedione and Cardiovascular Diseases
| Article | Year |
|---|---|
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV | 2013 |
10 other studies available for 2,4-thiazolidinedione and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Lik | 2023 |
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Ty | 2020 |
Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; | 2017 |
The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Diabetes Melli | 2018 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Do thiazolidinediones increase the risk of cardiovascular events?
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2008 |
A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
Topics: Advisory Committees; American Heart Association; Cardiovascular Diseases; Contraindications; Diabete | 2010 |
Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).
Topics: Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazo | 2002 |
[Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Topics: Administration, Oral; Cardiovascular Diseases; Cyclohexanes; Diabetes Complications; Diabetes Mellit | 2004 |
[The effects of thiazolidinedione from the cardiologic viewpoint].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; | 2005 |